You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Receptors, Ligands, and Catalysts on Demand using Expanded Genetic Alphabets

    SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC            Topic: 100

    ABSTRACTTechnology to deliveron demandmolecules that bind targets or catalyze reactions of choice has been a goal of chemistry foryearsEven todaytheory is inadequate to support de novo design of receptors having useful affinity or catalysts having useful turnoverThusmany have sought to create those catalysts on a DNA or RNAcollectivelyxNAusing the Darwinism to these biomolecules to evolveunder lab ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Application of PPODA QT for embolization of aneurysms

    SBC: ANEUVAS TECHNOLOGIES INC            Topic: 101

    A cerebral aneurysm is an abnormal enlargement or pouch that forms from a weakened vessel segment in the brain Often going unnoticed and untreated an aneurysm can cause a sudden and catastrophic hemorrhage or stroke Approximately of patients die from an aneurysm rupture even before receiving medical attention and of patients die despite medical treatment Patients that survive typical ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Regulators of NaV Channels Novel Anti Allodynic Drug Candidates

    SBC: Regulonix            Topic: 102

    PROJECT SUMMARY Chemotherapy induced peripheral neuropathy CIPN is a common prevalence and potentially dose limiting side effect of many cancer chemotherapy drug treatment regimens Clinically CIPN presents with pain that is burning shooting or electric shock like The increase in prevalence of cancer coupled with an increase in the cancer survival rates due to chemotherapy regimens ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Enabling point of care molecular diagnostics by developing an adaptive PCR instrument and on demand kit reagents

    SBC: BIOVENTURES, INC            Topic: 172

    Because of its high sensitivity polymerase chain reaction PCR is the gold standard for the diagnosis of many infectious diseases but generally only implemented in well equipped laboratories One of the major roadblocks for expanding PCR to point of care markets is the lack of simple robust single tube PCR designs which preserve its laboratory based high sensitivity and specificity In this F ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Therapeutic Administration of Suppressor of Cytokine Signaling Mimetics to Ameliorate Type Diabetes

    SBC: ONEVAX, LLC            Topic: NIAID

    Type Diabetes T D results from a breakdown of self tolerance that is characterized by immune cell mediated destruction of the insulin producing cells in the pancreas Ultimately glucose metabolism is interrupted resulting in the development of life threatening complications such as heart disease and renal failure T D affects an estimated million Americans with more than new patie ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Probabilistic Modeling for Software Guided Radiotherapy Patient Plan QA

    SBC: SUN NUCLEAR CORP.            Topic: 103

    Errors in the planning and delivery of radiation therapy can result in inferior outcomes for patients The magnitude of this problem is now well appreciated from cooperative group trials and other sources At present however there are few concrete tools to reduce the chance of plan errors passing undetected Current practice uses a variety of error mitigation means such as human inspection of th ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Identification of Small Molecule Amyloid Beta Peptide Reducing Agent

    SBC: Smart Biomolecules, Inc.            Topic: NIA

    Alzheimer s disease AD is a multifactorial heterogeneous and enormously complex disorder characterized by progressive intellectual deterioration Although remarkable advances have been made in unraveling the biological basis of the disease in the last two decades that immense knowledge has not been translated in to successful therapy With the failure of secretase inhibitors at the clinical tr ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Biomimetic Wound Healing Devices to Close Diabetic Wounds

    SBC: PROTEIN GENOMICS INC.            Topic: NIDDK

    The long term objective of this project is the synthesis and assembly of wound healing devices that mimic as closely as possible the biochemical and mechanical characteristics of healthy human skin The proposed research would focus on the synthesis of membranes containing electrospun human recombinant tropoelastin and collagen mixtures The ratios of the two molecules and the spinning condition ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Developing a novel therapy for diabetic retinopathy

    SBC: EVERGLADES BIOPHARMA LLC            Topic: W

    Project Summary Diabetic retinopathy DR is a leading cause of vision loss affecting about million people worldwide A major breakthrough in DR therapy is the recent approval of vascular endothelial growth factor VEGF inhibitors However anti VEGF therapy has limited efficacy with a number of side effects The critical barrier is how to identify other angiogenic targets for alternative or ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. A Randomized Blinded Placebo Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell LMSC Therapy for Treating The Metabolic Syndrome

    SBC: Longeveron LLC            Topic: NIA

    The metabolic syndrome MetS is a cluster of factors that increases the risks for cardiovascular disease type diabetes mellitus and mortality and currently affects andgt of US adults MetS is associated with endothelial dysfunction decreased circulating endothelial progenitor cells EPCs and a pro inflammatory state We have made the exciting discovery that therapy with allogeneic me ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government